Buscar
Sight Sciences Inc
SGHTAñadir a la lista de seguimiento
5.450USD
+0.010+0.18%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
291.54MCap. mercado
PérdidaP/E TTM
Más Datos de Sight Sciences Inc Compañía
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Información de Sight Sciences Inc
Símbolo de cotizaciónSGHT
Nombre de la empresaSight Sciences Inc
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoBadawi (Paul)
Número de empleados216
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 15
Dirección4040 Campbell Ave,
CiudadMENLO PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94025
Teléfono14158890550
Sitio Webhttps://www.sightsciences.com/
Símbolo de cotizaciónSGHT
Fecha de salida a bolsaJul 15, 2021
Director ejecutivoBadawi (Paul)
Ejecutivos de Sight Sciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Badawi
Mr. Paul Badawi
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.54M
+3.64%
Mr. Staffan Encrantz
Mr. Staffan Encrantz
Independent Chairman of the Board
Independent Chairman of the Board
2.07M
+2.05%
Dr. David Badawi, M.D.
Dr. David Badawi, M.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
1.80M
+2.22%
Ms. Alison Bauerlein
Ms. Alison Bauerlein
Chief Operating Officer, Principal Operating Officer
Chief Operating Officer, Principal Operating Officer
169.81K
-7.50%
Mr. Donald J. Zurbay, CPA
Mr. Donald J. Zurbay, CPA
Independent Director
Independent Director
103.61K
+27.28%
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
96.70K
+29.22%
Mr. Jeremy Bragg Hayden, J.D.
Mr. Jeremy Bragg Hayden, J.D.
Chief Legal Officer
Chief Legal Officer
87.27K
-40.39%
Mr. Gerhard F. (Gary) Burbach
Mr. Gerhard F. (Gary) Burbach
Independent Director
Independent Director
73.18K
+38.62%
Dr. Tamara R. Fountain, M.D.
Dr. Tamara R. Fountain, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Rodberg
Mr. Jim Rodberg
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Badawi
Mr. Paul Badawi
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.54M
+3.64%
Mr. Staffan Encrantz
Mr. Staffan Encrantz
Independent Chairman of the Board
Independent Chairman of the Board
2.07M
+2.05%
Dr. David Badawi, M.D.
Dr. David Badawi, M.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
1.80M
+2.22%
Ms. Alison Bauerlein
Ms. Alison Bauerlein
Chief Operating Officer, Principal Operating Officer
Chief Operating Officer, Principal Operating Officer
169.81K
-7.50%
Mr. Donald J. Zurbay, CPA
Mr. Donald J. Zurbay, CPA
Independent Director
Independent Director
103.61K
+27.28%
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
96.70K
+29.22%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Sight Sciences Inc?
Los cinco principales accionistas de Sight Sciences Inc son: Mr. Paul Badawi
¿Cuántas instituciones poseen acciones de Sight Sciences Inc (SGHT)?
A fecha de 2026Q1, 200 instituciones poseen acciones de Sight Sciences Inc, con un valor de mercado combinado de aproximadamente 27.85M, lo que representa el 51.74% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 944720.00.